KEYNOTE-495/KeyImPaCT: Updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer Meeting Abstract
| Authors: | Herbst, R.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J.; Lee, J. S.; Yang, N. C. H.; Garon, E.; Finocchiaro, G.; Ahn, M. J.; Luft, A.; Landers, G.; Basso, A.; Ma, H.; Kobie, J.; Palcza, J.; Cristescu, R.; Fong, L.; Snyder, A.; Yuan, J. D.; Gutierrez, M. |
| Abstract Title: | KEYNOTE-495/KeyImPaCT: Updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A666 |
| Language: | English |
| ACCESSION: | WOS:000919423400595 |
| DOI: | 10.1136/jitc-2022-SITC2022.0635 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 635 -- Source: Wos |
